Skip to content

The effect of different doses of Granisetron on preventing post-operative shivering in septoplasty

The effect of different doses of Granisetron on preventing postoperative shivering in patients undergoing septoplasty under general anesthesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201411173915N11
Enrollment
90
Registered
2014-12-04
Start date
2014-03-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shivering after septoplasty. Complications of medical and surgical care

Interventions

Intervention 1: Group A: intravenous granisetrone 1 mg diluted with 5 ml saline normal before induction of general anesthesia. Intervention 2: Group B: intravenous granisetrone 3 mg diluted with 5 ml
Treatment - Drugs
Group A: intravenous granisetrone 1 mg diluted with 5 ml saline normal before induction of general anesthesia
Group B: intravenous granisetrone 3 mg diluted with 5 ml normal saline before induction of general anesthesia
Group C: 5 ml intravenous saline normal before induction of general anesthesia

Sponsors

Research Vice Chancellor for Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 18-60 yr; ASA class 1-2; elective septoplasty surgery. Exclusion criteria: cardio-respiratory diseases; infections; body temperature less than 36.5?°C and more than 38°C; allergy to serotonin antagonist drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Post operative shivering. Timepoint: Till 2 hours after surgery. Method of measurement: Clinical assessment.

Secondary

MeasureTime frame
Need for petidine administration. Timepoint: Till 2 hours after surgery. Method of measurement: Clinical assessment.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ali Peirovifar

Tabriz University of Medical Sciences

peirovifara@gmail.com+98 41 3334 7054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026